A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.

GNbAC1 is a humanized monoclonal antibody targeting MSRV-Env, an endogenous retroviral protein, which is expressed in multiple sclerosis (MS) lesions, is pro-inflammatory and inhibits oligodendrocyte precursor cell differentiation. This paper describes the open-label extension up to 12months of a trial testing GNbAC1 in 10 MS patients at 2 and 6mg/kg. The primary objective was to assess GNbAC1 safety, and other objectives were pharmacokinetic and pharmacodynamic assessments. During the extended study, no safety issues occurred in the 8 remaining patients. No anti-GNbAC1 antibodies were detected. GNbAC1 appears well tolerated.

Osteopaattisen hoidon vaikutukset purentaelimen dysfunktion oireisiin

Tämän opinnäytetyön tarkoituksena oli selvittää osteopaattisten manuaalisen hoidon vaikutusta purentaelimen dysfunktiosta johtuviin oireisiin. Lisäksi teimme osteopaattisen tutkimus- ja hoitomallin osteopaattien käyttöön. Tutkimukseen osallistui kaksitoista potilasta. Erikoishammaslääkäri, professori Pentti Kemppainen valikoi YTHS:n potilaskannasta opinnäytetyöhön tulevat potilaat ja HLL Seija Taube teki valituille potilaille aloitusvaiheen hammaslääketieteellisen purentafysiologisen tutkimuksen. Opinnäytetyöhön ei otettu potilaita, joiden vaivana olivat yliliikkuvat leukanivelet, leukanivelen nivelrikko tai leukanivelten reuma yms. sairaudet. Valintakriteereinä olivat tutkimushenkilöiden kokema kipu posken ja ohimon alueella ja leukanivelen liikerajoitus. Tutkimus ja hoitokertoja oli neljä, viikon välein. Ensimmäisellä hoitokerralla potilaat vastasivat kyselylomakkeeseen, jossa kartoitimme VAS- janan avulla, oliko heillä ilmennyt viimeisen 6kk aikana päänsärkyä, kipua pureskellessa ja kipua suuta avatessa. Kartoitimme kyselylomakkeessa myös oliko heillä ollut leukanivelen naksumista, lukkiutumista, korvien tukkoisuutta ja korvien soimista. Osteopaattinen hoito koostui lihastekniikoista, leukanivelen artikulaatiosta, lihaskalvoihin kohdistuvista tekniikoista ja kraniaalitekniikoista. Viimeisen käynnin yhteydessä potilaat saivat saman kyselylomakkeen kuin tullessa. Lisäksi kysyimme kokivatko he oireiden lievittyneen hoitojakson jälkeen ja oliko potilaista hoidolla ollut vaikutusta oireiden lievittymiseen. Pyysimme potilaita vastaamaan lomakkeeseen viikon kuluttua viimeisestä hoitopäivästä. Hoidot toteutettiin Kunto-Stadian tiloissa keväällä 2006. Tutkimustulokset on analysoitu Wilcoxonin merkkitestillä. Tutkimustuloksista tilastollisesti merkitsevä muutos oli päänsäryn väheneminen (P=0,004).

L'anticoagulation du patient âgé en fibrillation atriale: que prescrivent les cardiologues, les gériatres et les médecins généralistes [Anticoagulation in the aged patient with atrial fibrillation: What are prescribing cardiologists, geriatricians and general practitioners?].

OBJECTIVE: To assess prescribing of anticoagulants in atrial fibrillation (AF) in the elderly, both a quantitative point of view (rate of anticoagulation) and qualitative (type of anticoagulation). Determinants of prescribing and non-prescribing were also analysed. METHODS: Prospective survey of practice, based on one clinical case and questionnaire conducted in 60 practitioners (20 cardiologists [C], 20 geriatricians [G] and 20 general practitioners [GP]). RESULTS: In reading the clinical case, 88.3% of physicians would have initiated a treatment; three types of treatments would have been chosen: AVK (68.3%), ODA (20.0%) and platelet antiaggregant (11.7%). Criteria taken into account to initiate anticoagulation varied according to the specialty. Cardiologists considered more the age criteria (C: 95.0%, G: 75.0%, MG: 60.0%; P<0.05), diabetes (C: 90.0%, G: 60.0%, MG: 55.0%; P<0.05), hypertension (C: 85.0%, G: 55.0%, MG: 60.0%; P<0.05) and female gender (C: 80.0%, G: 35.0%, MG: 25.0%; P<0.05). The quality of renal function was however a more secondary criteria (C: 15.0%, G: 5.0%, MG: 0.0%; P<0.05). General practitioners considered most frequently the presence of underlying heart disease (C: 35.0%, G: 5.0%, MG: 45.0%; P<0.05) as well as usual cardiovascular risk factors (overweight, dyslipidaemia; P<0.05). Risk of bleeding, however, was observed by 76.7% of physicians in the clinical situation presented (C: 70.0%, G: 75.0%, MG: 85.0%; P<0.05). CONCLUSION: This survey confirms that the FA remains under anticoagulated in the elderly and the barriers to the prescription of oral anticoagulation are often without rational basis.

Tutkijoita välitilassa?

Kirja-arvio

Making SENSE - Sustained Effort Network for treatment of Status Epilepticus as a multicenter prospective registry.

BACKGROUND: Evidence regarding the different treatment options of status epilepticus (SE) in adults is scarce. Large randomized trials cover only one treatment at early stage and suggest the superiority of benzodiazepines over placebo, of intravenous lorazepam over intravenous diazepam or over intravenous phenytoin alone, and of intramuscular midazolam over intravenous lorazepam. However, many patients will not be treated successfully with the first treatment step. A large randomized trial covering the treatment of established status (ESETT) has just been funded recently by the NIH and will not start before 2015, with expected results in 2018; a trial on the treatment of refractory status with general anesthetics was terminated early due to insufficient recruitment. Therefore, a prospective multicenter observational registry was set up; this may help in clinical decision-making until results from randomized trials are available. METHODS/DESIGN: SENSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patient characteristics, treatment modalities and in-house outcome of consecutive adults admitted for SE treatment in each of the participating centres and to identify predictors of outcome. Pre-treatment, treatment-related and outcome variables are documented systematically. To allow for meaningful multivariate analysis in the patient subgroups with refractory SE, a cohort size of 1000 patients is targeted. DISCUSSION: The results of the study will provide information about risks and benefits of specific treatment steps in different patient groups with SE at different points of time. Thus, it will support clinical decision-making and, furthermore, it will be helpful in the planning of treatment trials. TRIAL REGISTRATION: DRKS00000725.

Tahko Pihkalan kokoelma

Prof. Lauri Pihkalan testamentin perusteella Jyväskylän yliopiston kirjastolle luovutettu kokoelma koti- ja ulkomaista urheilukirjallisuutta 1800-luvun loppupuolelta 1970-luvulle. Sisältää urheilua ja ruumiinkulttuuria käsittelevän kirjallisuuden lisäksi poliittista historiaa, sotalaitosta ja naisliikettä koskevaa kirjallisuutta sekä ainutlaatuisen Amerikka-kokoelman. Kirjoissa näkyy Pihkalan lukutavat ja merkinnät.